Wells Fargo & Company Has Lowered Expectations for Stryker (NYSE:SYK) Stock Price

Key Points

• Wells Fargo lowered its price target on Stryker to $418 from $456 while keeping an "overweight" rating, and several other firms have trimmed targets leaving a consensus target near $411.20 and a "Moderate Buy" consensus.
• Stryker missed Q1 estimates (EPS $2.60 vs. $2.98 expected; revenue $6.02B vs. $6.34B), sending the stock down to $305.91, though management reaffirmed FY‑2026 guidance (adjusted EPS $14.90–$15.10; organic sales growth 8%–9.5%) and said it is recovering from a cyber incident.
• Insider selling noted: Director Ronda E. Stryker sold 250,000 shares for about $90.7M (a 9.23% reduction in her stake), and with roughly 77% institutional ownership, continued insider/institutional selling could add downward pressure on the shares.

Stryker (NYSE:SYK - Get Free Report) had its price target lowered by stock analysts at Wells Fargo & Company from $456.00 to $418.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an "overweight" rating on the medical technology company's stock. Wells Fargo & Company's target price suggests a potential upside of 36.64% from the company's previous close.

Several other analysts have also recently weighed in on the stock. TD Cowen cut shares of Stryker from a "buy" rating to a "hold" rating and set a $387.00 price objective on the stock. in a research note on Monday, January 26th. Wall Street Zen cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Saturday, April 18th. Citigroup decreased their price target on shares of Stryker from $420.00 to $385.00 and set a "buy" rating on the stock in a research note on Tuesday, April 7th. Robert W. Baird set a $437.00 price target on shares of Stryker in a research note on Friday, January 30th. Finally, The Goldman Sachs Group decreased their price target on shares of Stryker from $403.00 to $357.00 and set a "neutral" rating on the stock in a research note on Thursday, April 9th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $411.20.

Stryker Price Performance

Stryker stock traded down $9.22 during trading hours on Friday, hitting $305.91. 713,758 shares of the stock were exchanged, compared to its average volume of 2,040,748. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock has a market capitalization of $117.16 billion, a P/E ratio of 36.59, a P/E/G ratio of 1.84 and a beta of 0.92. Stryker has a 12 month low of $302.22 and a 12 month high of $404.87. The business's 50-day moving average is $345.67 and its two-hundred day moving average is $356.95.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts expect that Stryker will post 14.91 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stryker

Large investors have recently bought and sold shares of the business. Sankala Group LLC acquired a new position in Stryker in the fourth quarter valued at approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker in the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new position in Stryker in the fourth quarter valued at approximately $28,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reaffirmed its FY‑2026 outlook (organic sales growth 8%–9.5%; adjusted EPS $14.90–$15.10) and said it is recovering from a recent cyber incident — supports upside if execution continues. Article Title
• Positive Sentiment: Operating cash flow, net income and reported EPS showed strength (cash from operations surged materially year‑over‑year), indicating solid underlying cash generation despite near‑term revenue pressure. Article Title
• Positive Sentiment: Stryker will present at the Bank of America Global Healthcare Conference (May 13), giving management an opportunity to reinforce guidance, address the cyber incident and engage investors. Article Title
• Neutral Sentiment: Wall Street still shows overall positive tilt (several buy/overweight ratings remain and median price target in recent data is elevated), which could limit downside if guidance holds. Article Title
• Neutral Sentiment: Full Q1 press‑conference transcript and earnings call are available for details on segment trends and recovery timelines (useful for investors wanting management commentary). Article Title
• Negative Sentiment: Q1 results missed estimates: adjusted EPS $2.60 vs. consensus around $2.98 and revenue $6.02B vs. ~$6.34B — headline misses are pressuring the share price. Article Title
• Negative Sentiment: Several firms lowered price targets (Needham: $454 → $418; BTIG: $397 → $379; Truist cut its PT), which can weigh on sentiment even when ratings remain “buy.” Article Title Article Title
• Negative Sentiment: Management flagged softer demand in some implant and complex‑procedure categories — cyber incident disruption amplified near‑term demand weakness. Article Title
• Negative Sentiment: Significant insider and institutional selling noted in recent filings/data, which can add pressure to shares if sustained. Article Title

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.